<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医麦客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-18T16:11:17+08:00</updated>
  <subtitle>医麦客是一个聚焦转化医学、精准医疗和生物制药的专业媒体平台，持续关注体外诊断、抗体药物、细胞治疗、基因治疗等细分领域。为新生物医药医疗领域的企业发声，推动企业和行业的快速发展。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>1000万美元IND里程碑付款，礼来和Dicerna合作的RNAi疗法将启动心脏代谢性疾病的临床研究丨医麦猛爆料</title>
    <updated>2020-11-18T13:26:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/vL4u_Pc2WxD8mbd-viS-nw</id>
    <link href="https://mp.weixin.qq.com/s/vL4u_Pc2WxD8mbd-viS-nw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>4-1BB/5T4双抗即将进入临床开发阶段，国内哪些公司还在关注丨医麦猛爆料</title>
    <updated>2020-11-18T13:26:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/Y5hpsW6zMTGvQ5Xkbb99LA</id>
    <link href="https://mp.weixin.qq.com/s/Y5hpsW6zMTGvQ5Xkbb99LA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>有效率高达94.5%，EMA启动Moderna新冠候选疫苗的滚动审查程序丨医麦猛爆料</title>
    <updated>2020-11-18T13:26:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/aHAFCTnbOfvOBVT6DGYlXw</id>
    <link href="https://mp.weixin.qq.com/s/aHAFCTnbOfvOBVT6DGYlXw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>朱军教授：国内CAR-T研究数量多但原始创新不够，未来应深化研究做出中国特色</title>
    <updated>2020-11-18T13:26:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/1PPiRlJt3eH4f7F58DXziQ</id>
    <link href="https://mp.weixin.qq.com/s/1PPiRlJt3eH4f7F58DXziQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>靶向NKG2D，Nkarta“现货”CAR-NK完成首例患者给药 | 医麦猛爆料</title>
    <updated>2020-11-16T22:56:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/T6qkWAywg1alQUBgkf1F8A</id>
    <link href="https://mp.weixin.qq.com/s/T6qkWAywg1alQUBgkf1F8A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>天境、信达、康方公布CD47单抗最新临床研究数据，哪些公司还在押注CD47 | 医麦猛爆料</title>
    <updated>2020-11-16T22:56:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/dxlmVSutg6q2xGG2l4JWJw</id>
    <link href="https://mp.weixin.qq.com/s/dxlmVSutg6q2xGG2l4JWJw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>长达92周的耐久性！AAV基因疗法大幅度降低湿性AMD患者的治疗负担丨医麦猛爆料</title>
    <updated>2020-11-16T22:56:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/r4kJGGrcw8HCuE-mXlmJ2Q</id>
    <link href="https://mp.weixin.qq.com/s/r4kJGGrcw8HCuE-mXlmJ2Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」获近亿元融资，基因编辑公司瑞风生物预计明年准备申报β地贫疗法IND</title>
    <updated>2020-11-16T22:56:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/GViRtb0fVa4e4RjCcohW3w</id>
    <link href="https://mp.weixin.qq.com/s/GViRtb0fVa4e4RjCcohW3w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【重磅来袭】药物警戒及受试者权益保护国际研讨会暨CIOMS《药物性肝损伤（DILI）国际共识》发布会即将召开！</title>
    <updated>2020-11-16T22:56:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/2f2759S7SfHlS1wX1stUVQ</id>
    <link href="https://mp.weixin.qq.com/s/2f2759S7SfHlS1wX1stUVQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药融资丨深圳普瑞金生物药业有限公司完成1.4亿元B轮融资，并启动港股IPO</title>
    <updated>2020-11-15T23:31:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/GiDi8Y9qgV8w_LL9GZb30w</id>
    <link href="https://mp.weixin.qq.com/s/GiDi8Y9qgV8w_LL9GZb30w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>西比曼生物更新CD19/CD20双特异性CAR-T临床进展，治疗复发难治性B-NHL数据亮眼丨医麦猛爆料</title>
    <updated>2020-11-15T23:31:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/n0Sx3Viao01a4GzZlRj43A</id>
    <link href="https://mp.weixin.qq.com/s/n0Sx3Viao01a4GzZlRj43A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>从License-in到License-out，中国生物创新型药企走出国门 | 医麦新观察</title>
    <updated>2020-11-15T23:31:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/AAl1rnsql48jEOY1Y5g-Og</id>
    <link href="https://mp.weixin.qq.com/s/AAl1rnsql48jEOY1Y5g-Og" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>暴露肿瘤细胞，隐藏健康细胞！CD33 CAR-T搭配新型造血干细胞对抗AML丨医麦猛爆料</title>
    <updated>2020-11-15T23:31:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/ygYTvzRpqjJLsQaQjoYdCg</id>
    <link href="https://mp.weixin.qq.com/s/ygYTvzRpqjJLsQaQjoYdCg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>千面新原力：千名科学家及企业家共话生物医药未来</title>
    <updated>2020-11-15T23:31:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/1W7GTI6wapW46RuR9-YZrA</id>
    <link href="https://mp.weixin.qq.com/s/1W7GTI6wapW46RuR9-YZrA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH 2020：NK细胞治疗在血液疾病的新进展丨医麦新观察</title>
    <updated>2020-11-15T11:51:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/zynyh2OE_tzeK1vDuzI1VA</id>
    <link href="https://mp.weixin.qq.com/s/zynyh2OE_tzeK1vDuzI1VA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Nature综述：PD-1/L1抑制剂的联合用药在其临床试验中已居C位丨医麦新观察</title>
    <updated>2020-11-15T11:51:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/GtTE-H6K-12PJU0lcBhT4g</id>
    <link href="https://mp.weixin.qq.com/s/GtTE-H6K-12PJU0lcBhT4g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>胰腺癌精准治疗新希望！新型ADC抗肿瘤效果最优 | 医麦猛爆料</title>
    <updated>2020-11-15T11:51:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/d9iSQbek3CbOJzEAb7wjWg</id>
    <link href="https://mp.weixin.qq.com/s/d9iSQbek3CbOJzEAb7wjWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新型“现货”CAR-T在显示出对实体瘤的治疗潜力，同种异体策略是未来的发展趋势丨医麦猛爆料</title>
    <updated>2020-11-14T11:08:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-14:/s/1NySyQvCgL0dzQsmibhBFg</id>
    <link href="https://mp.weixin.qq.com/s/1NySyQvCgL0dzQsmibhBFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>三叶草生物与澳斯康生物制药签署战略合作协议，加速“S-三聚体”亚单位新冠疫苗产业化</title>
    <updated>2020-11-14T11:08:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-14:/s/4_B0XIEXL5OI5zdRzCJvrg</id>
    <link href="https://mp.weixin.qq.com/s/4_B0XIEXL5OI5zdRzCJvrg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复星医药和 BioNTech宣布其mRNA候选疫苗BNT162b2 获中国国家药监局临床试验批准</title>
    <updated>2020-11-14T11:08:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-14:/s/tc6-iGQ1N-IzJ45ByK1kJA</id>
    <link href="https://mp.weixin.qq.com/s/tc6-iGQ1N-IzJ45ByK1kJA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>